CRISPR/Cas9 technology into breakthrough equine therapeutics. Our lead program targets equine herpes and Coggins diseases.

Our company’s unique strengths include the expertise of our team in discovering, manipulating and developing genome editing products using a proprietary versatile lipid nanoparticle delivery system. EquiTech's focus is on both in vivo and ex vivo product development which can help control or even eradicate diseases in our livestock. Such discoveries are eminent in research as they can be extrapolated later for human studies to find cures.